middle.news
Nova Eye Medical Narrows EBITDA Loss with 23% Sales Growth and New US Product Feature
9:02am on Wednesday 29th of April, 2026 AEST
•
Healthcare
Read Story
Nova Eye Medical Narrows EBITDA Loss with 23% Sales Growth and New US Product Feature
9:02am on Wednesday 29th of April, 2026 AEST
Key Points
23% quarterly sales growth to US$5.8 million
Positive EBITDA from operations for first time
First sales of iTrack™ Advance in China
Green illumination added to US iTrack™ device
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Nova Eye Medical (ASX:EYE)
OPEN ARTICLE